Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.